Discrepant results in the interpretation of HIV-1 drug-resistance genotypic data among widely used algorithms

HIV Medicine

Volumn 4, Issue 1, 2003, Pages 72-78

  Kijak, G H ^a   Rubio, A E ^a   Pampuro, S E ^a   Zala, C ^b   Cahn, P ^b   Galli, R ^c   Montaner, J S ^c   Salomón, Horacio ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b Huesped Foundation   (Argentina)

^c ST PAUL S HOSPITAL   (Canada)

Author keywords

Algorithms; Databases; Genotyping tests; HIV 1 drug resistance

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ALGORITHM; ARTICLE; CONTROLLED STUDY; DATA ANALYSIS; DATA BASE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; SAMPLE; TREATMENT FAILURE; ANTIBIOTIC RESISTANCE; BIOLOGY; DRUG EFFECT; GENETICS; METHODOLOGY; REPRODUCIBILITY; VIROLOGY;

ALGORITHMS; ANTI-HIV AGENTS; COMPUTATIONAL BIOLOGY; DATABASES; DRUG RESISTANCE, VIRAL; GENOTYPE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; REPRODUCIBILITY OF RESULTS; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT FAILURE;

EID: 0037271788     PISSN: 14642662     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-1293.2003.00131.x     Document Type: Article

References (33)

1. Palella FJ Jr, Delaney KM, Moorman AC et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338: 853-860.
2. Richman DD. Principles of HIV resistance testing and overview of assay performance characteristics. Antiviral Ther 2000; 5: 27-31.
3. Hanna GJ, D'Aquila RT. Clinical use of genotypic and phenotypic drug resistance testing to monitor antiretroviral chemotherapy. Clin Infect Dis 2001; 32: 774-782.
4. Harrigan PR, Cote HC. Clinical utility of testing human immunodeficiency virus for drug resistance. Clin Infect Dis 2000; 30: S117-S122.
5. Demeter L, Haubrich R. International perspectives on antiretroviral resistance. Phenotypic and genotypic resistance assays. methodology, reliability, and interpretations. J Acquir Immune Defic Syndr 2001; 26: S3-S9.
6. Baxter JD, Mayers DL, Wentworth DN et al. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. AIDS 2000; 14: F83-F93.
7. Durant J, Clevenbergh P, Halfon P et al. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet 1999; 353: 2195-2199.
8. Cingolani A, Antinori A, Rizzo MG et al. Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA). AIDS 2002; 16: 369-379.
9. Cohen CJ, Hunt S, Sension M et al. A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. AIDS 2002; 16: 579-588.
10. Melnick D, Rosenthal J, Cameron M et al. Impact of phenotypic antiretroviral drug resistance testing on the response to salvage antiretroviral therapy (ART) in heavily experienced patients. 7th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, January-February 2000 [Abstract 786].
11. Meynard JL, Vray M, Morand-Joubert L et al. Phenotypic or genotypic resistance testing for choosing ntiretroviral therapy after treatment failure: a randomized trial. AIDS 2002; 16: 727-736.
12. Hirsch MS, Brun-Vezinet F, D'Aquila RT et al. Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. JAMA 2000; 283: 2417-2426.
13. Department of Health and Human Services. Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents. http://www.hivatis.org/guidelines/adult/Aug13-01/pdf/AAAug13S.PDF. Last accessed 21 November 2001.
14. BHIVA Writing Committee on behalf of the BHIVA Executive Committee: British HIV Association 2001, (BHIVA). Guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV MED 2001; 2: 276-313.
15. EuroGuidelines Group. The EuroGuidelines Group for HIV resistance. Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting. AIDS 2001; 15: 309-320.
16. Ledesma E, Soriano V. Spanish consensus conference on drug resistance testing in clinical practice. HIV drug resistance Spanish panel. AIDS 1999; 13: 1998-2001.
17. Kantor R, Machekano R, Gonzales MJ, Dupnik K, Shapiro JM, Shafer RW. Human immunodeficiency virus reverse transcriptase and protease sequence database: an expanded data model integrating natural language text and sequence analysis programs. Nucleic Acids Res 2001; 29: 296-299.
18. Larder BA, Kemp SD, Hertogs K. Quantitative prediction of HIV-1 phenotypic drug resistance from genotypes: the virtual phenotype (VirtualPhenotype). Antiviral Ther 2000; 5 (Suppl. 3): 49.
19. DeGruttola V, Dix L, D'Aquila R, Holder D et al. The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antiviral Ther 2000; 5: 41-48.
20. Rousseau MN, Vergne L, Montes B et al. Patterns of resistance mutations to antiretroviral drugs in extensively treated HIV-1-infected patients with failure of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2001; 26: 36-43.
21. Tural C, Ruiz L, Holtzer C et al. Utility of HIV genotyping and clinical expert advice-the Havana Trial. Antiviral Ther 2001; 6: S31.
22. Carpenter CC, Cooper DA, Fischl MA et al. Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. JAMA 2000; 283: 381-390.
23. Hertogs Y, de Bethune MP, Miller V et al. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrob Agents Chemother 1998; 42: 269-276.
24. Larder BA, Kohli A, Kellam P, Kemp SD, Kronick M, Henfrey RD. Quantitative detection of HIV-1 drug resistance mutations by automated DNA sequencing. Nature 1993; 365: 671-673.
25. Larder BA, Kellam P, Kemp SD. Convergent combination therapy can select viable multidrug-resistant HIV-1 in vitro, Nature 1993; 365: 451-453.
26. Cohen J. A coefficient of agreement for nominal scales. Educational Psychological Measurement 1960; 20: 37-46.
27. Schmidt B, Korn K, Moschik B et al. Comparison of different algorithms for the interpretation of genotypic data for protease inhibitors. Antiviral Ther 2000; 5 (Suppl. 3): 61.
28. Schmidt B, Walter H, Schwingel E et al. Comparison of different interpretation systems for genotypic HIV-1 drug resistance data. Antiviral Ther 2001; 6 (Suppl. 1): 102.
29. Shafer RW, Gonzales MJ, Brun-Vézinet F. Online comparison of HIV-1 drug resistance algorithms identifies rates and causes of discordant interpretations. Antiviral Ther 2001; 6 (Suppl. 1): 101.
30. Dunne AL, Mitchell FM, Coberly SK et al. Comparison of genotyping and phenotyping methods for determining susceptibility of HIV-1 to antiretroviral drugs. AIDS 2001; 15: 1471-1475.
31. Kozal MJ, Shah N, Shen N et al. Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays. Nat Med 1996; 2: 753-759.
32. Beinker NK, Mayers DL, Lange CG et al. Genotypic drug resistance and cause of death in HIV-infected persons who died in 1999. J Acquir Immune Defic Syndr 2001; 28: 250-253.
33. IAS-USA Drug Resistance Mutations Group. Update on Drug Resistance Mutations in HIV-1. http://www.iasusa.org/resistance_mutations/revisedmutafigures-11. 30.01.pdf. Accessed on 8 February 2001.